GLP-1 Weight-Loss Drugs Prompt Cannabis Retailers to Rework Product Advice
The rapid uptake of GLP-1 class weight-loss medications is altering consumer behavior in the roughly $40 billion U.S. cannabis market, industry participants and experts say. Retailers are adjusting recommendations on edibles and inhalable products as users on GLP-1 therapies report reduced appetite and uncertainty around altered effects, while rese…